Form 13-F position report

C4 THERAPEUTICS INC

Reported by Bain Capital Life Sciences Investors LLC

Company profile Manager portfolio Source filing
CCCC CUSIP 12529R107 Manager CIK 0001703031
Latest reported change

Reported 1,642,210 shares, unchanged from the prior quarter.

Reported value -24.7%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 3.87% This manager · Q1 2022
Shares 1,642,210 Quarter-end amount reported
Reported value $39,840,000 Fair value at quarter end
Consecutive quarters held 6 Through Q1 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q2 2026 Unchanged 7,171,910 0 (0.0%) 1.99% $33,492,820 2026-08-14
Q1 2026 Unchanged 7,171,910 0 (0.0%) 1.7% $18,862,123 2026-05-15
Q4 2025 Added 7,171,910 +6,060,000 (545.0%) 1.05% $13,698,348 2026-02-17
Q3 2025 Unchanged 1,111,910 0 (0.0%) 0.16% $2,468,440 2025-11-14
Q2 2025 Unchanged 1,111,910 0 (0.0%) 0.2% $1,590,031 2025-08-14
Q1 2025 Unchanged 1,111,910 0 (0.0%) 0.26% $1,779,056 2025-05-15
Q4 2024 Unchanged 1,111,910 0 (0.0%) 0.47% $4,002,876 2025-02-14
Q3 2024 Unchanged 1,111,910 0 (0.0%) 0.66% $6,337,887 2024-11-14
Q2 2024 Reduced 1,111,910 -30,300 (-2.7%) 0.56% $5,137,024 2024-08-12
Q1 2024 Reduced 1,142,210 -500,000 (-30.4%) 0.75% $9,331,856 2024-05-15
Q4 2023 Unchanged 1,642,210 0 (0.0%) 0.89% $9,278,487 2024-02-13
Q3 2023 Unchanged 1,642,210 0 (0.0%) 0.34% $3,054,511 2023-11-14
Q2 2023 Unchanged 1,642,210 0 (0.0%) 0.47% $4,516,078 2023-08-14
Q1 2023 Unchanged 1,642,210 0 (0.0%) 0.64% $5,157,000 2023-05-15
Q4 2022 Unchanged 1,642,210 0 (0.0%) 1.08% $9,689,000 2023-02-14
Q3 2022 Unchanged 1,642,210 0 (0.0%) 1.72% $14,402,000 2022-11-14
Q2 2022 Unchanged 1,642,210 0 (0.0%) 1.45% $12,382,000 2022-08-15
Q1 2022 Unchanged 1,642,210 0 (0.0%) 3.87% $39,840,000 2022-05-16
Q4 2021 Added 1,642,210 +1 (0.0%) 4.19% $52,879,000 2022-02-14
Q3 2021 Unchanged 1,642,209 0 (0.0%) 4.55% $73,374,000 2021-11-15
Five years are shown. A free account unlocks the complete reported history. Unlock full history
Institutional context

Who else reported the position

147 managers reported C4 THERAPEUTICS INC for Q1 2022.

Manager Activity Shares Change % of reported 13F Reported value Tenure
RTW INVESTMENTS LP Added 4,531,982 +2,037,017 2.28% $109,946,000 6 qtrs
PRICE T ROWE ASSOCIATES INC MD Added 4,377,372 +292,574 0.01% $106,195,000 6 qtrs
BlackRock Inc Reduced 3,139,990 -265,992 < 0.01% $76,177,000 6 qtrs
STATE STREET CORPORATION Added 2,227,759 +638,006 < 0.01% $54,045,000 6 qtrs
PERCEPTIVE ADVISORS LLC Reduced 2,082,723 -126,190 1.01% $50,526,000 6 qtrs
VANGUARD GROUP INC Added 2,022,142 +5,683 < 0.01% $49,057,000 6 qtrs
ArrowMark Colorado Holdings LLC Added 1,909,023 +134,519 0.41% $46,313,000 6 qtrs
Bain Capital Life Sciences Investors LLC This report Unchanged 1,642,210 0 3.87% $39,840,000 6 qtrs
WASATCH ADVISORS INC Added 1,538,525 +243,063 0.18% $37,325,000 5 qtrs
PICTET ASSET MANAGEMENT SA Added 1,131,441 +70,813 0.03% $27,449,000 3 qtrs
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2022
Filed
May 16, 2022
Filing type
13F-HR
Position type
COM STK

Voting authority reported

Sole
1,642,210
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.